Yin and colleagues found an association of LAPTM4B expression with stage III and chemotherapy resistance in patients who are taking PAC (cisplatin, epirubicin and cyclophosphamide) regimen in ovarian cancer (Yin et al., 2011). Here, LAPTM4B is linked to ovarian cancer.